Innovation meets superior patient care with this never-before-seen Type I ambulance, purpose-built for first responders with ...
Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusions needed to one per month.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback